Corrects company name to "Concentra" in bullet 3, corrects typographical error in bullet 5
** Shares of drug developer Acelyrin SLRN.O fall 12.7% to $2.30
** SLRN reiterates its planned merger with Alumis, says unsolicited buyout offer from Concentra Biosciences is not expected to result in superior proposal
** Concentra last month offered to buy Acelyrin for about $300 million, according to Reuters calculations
** SLRN early in February agreed to merge with Alumis in all-stock transaction
** Transaction is expected to close by Q2 2025
** SLRN stock has fallen 67.3% in past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。